Goodrx Holdings, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Justin Fengler, See Remarks of GoodRx Holdings, Inc., reported multiple transactions in common stock on October 15, 2026.
NASDAQ
Thomas (Tc) Chan, Chief Accounting Officer of GoodRx Holdings, Inc., reported multiple transactions in common stock on October 15, 2026.
NASDAQ
Wendy Lynn Barnes, See Remarks and a Director of GoodRx Holdings, Inc., reported multiple transactions in common stock on October 15, 2026.
NASDAQ
Thomas (Tc) Chan, Chief Accounting Officer of GoodRx Holdings, Inc., reported multiple transactions in common stock on September 15, 2026.
NASDAQ
Justin Fengler, See Remarks of GoodRx Holdings, Inc., reported multiple transactions in common stock on September 15, 2026.
NASDAQ
Francisco Partners Iv, L.P. and 4 others reported changes in beneficial ownership of GoodRx Holdings, Inc. common stock on August 24, 2026.
NASDAQ
Francisco Partners Iv, L.P. and 4 others reported changes in beneficial ownership of GoodRx Holdings, Inc. common stock on August 19, 2026.
NASDAQ
Thomas (Tc) Chan, Chief Accounting Officer of GoodRx Holdings, Inc., reported multiple transactions in common stock on August 15, 2026.
NASDAQ
Justin Fengler, See Remarks of GoodRx Holdings, Inc., reported multiple transactions in common stock on August 15, 2026.
NASDAQ
Justin Fengler, See Remarks of GoodRx Holdings, Inc., received 190,204 shares of common stock on August 10, 2026.
NASDAQ
Christopher A Mcginnis, See Remarks of GoodRx Holdings, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Wendy Lynn Barnes, See Remarks and a Director of GoodRx Holdings, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Thomas (Tc) Chan, Chief Accounting Officer of GoodRx Holdings, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Director Agnes Rey-Giraud was granted 73,434 restricted stock units in GoodRx Holdings, Inc.
NASDAQ
GoodRx Holdings, Inc. director Kelly J. Kennedy was granted 73,434 restricted stock units as part of standard equity compensation.
NASDAQ
Director Douglas Hirsch was granted 73,434 deferred stock units as part of his compensation package with GoodRx Holdings, Inc.
NASDAQ
GoodRx Holdings, Inc. director Ronald E. Bruehlman was granted 73,434 deferred stock units as part of his annual compensation.
NASDAQ
Director Trevor Bezdek acquired 73,434 restricted stock units in GoodRx Holdings, Inc. as part of an equity compensation grant.
NASDAQ
Director Scott Wagner was granted 73,434 restricted stock units as part of his compensation package with GoodRx Holdings, Inc.
NASDAQ
GoodRx Chief Accounting Officer Thomas Chan acquired Class A common stock through RSU vesting and subsequently sold a portion to cover tax obligations.
NASDAQ
Director Trevor Bezdek was granted 110,294 restricted stock units as part of his compensation package with GoodRx Holdings, Inc.
NASDAQ
Director Douglas Hirsch was granted 4,642 deferred stock units as part of his compensation package with GoodRx Holdings, Inc.
NASDAQ
Director Ronald E. Bruehlman was granted 4,642 deferred stock units as part of his compensation package with GoodRx Holdings, Inc.
NASDAQ
GoodRx Holdings, Inc. Chief Accounting Officer Thomas Chan acquired 5,575 shares through RSU vesting and disposed of 2,838 shares to cover tax obligations.
NASDAQ
GoodRx Holdings CFO Christopher A. McGinnis acquired 44,779 shares through RSU vesting and disposed of 19,726 shares to cover tax obligations.
NASDAQ
GoodRx Holdings, Inc. Chief Accounting Officer Thomas Chan was granted 54,494 restricted stock units on May 11, 2026.
NASDAQ
GoodRx Holdings CFO Christopher McGinnis acquired 36,987 shares via RSU vesting and disposed of 10,745 shares for tax obligations.
NASDAQ
GoodRx CEO Wendy Barnes acquired 277,288 shares through RSU vesting and disposed of 120,456 shares to cover tax obligations.
NASDAQ
GoodRx Holdings Director Agnes Rey-Giraud exercised stock options and transferred shares to a family trust, adjusting her beneficial ownership.
NASDAQ
GoodRx Holdings, Inc. Chief Financial Officer Christopher A McGinnis was granted 443,852 restricted stock units, vesting quarterly over three years.